0:04
Thank you very much.
0:05
I'm good afternoon everyone.
0:07
I'm Torbjorn Furuseth I’m a Co, founder of DoMore Diagnostics and I'll give you a short introduction as to how we at DoMore Diagnostics personalise cancer treatment with the use of AI. And digital AI biomarkers is a new modality that will revolutionise precision medicine.
0:27
And what you see on this screen is a tumour.
0:31
And this holds the key information of the aggressiveness of the tumour and the potential benefit of treatment.
0:38
The genomic profile is important to understand this, but it's only one piece.
0:43
And but this has been the main focus of precision medicine so far.
0:48
But there are many other factors, the epigenetics, so the expression of the genes and the transcription, the interplay between the genes and then seeing how it really plays out in the tissue patterns, a phenotype of the tumour.
1:02
The stroma, so that's the connective tissue around the tumour is also very important to understand the metastatic pattern of the cancer, the heterogeneity, the internal variation within the tumour.
1:14
You see within this tumour there's a lot of variation and really getting a sense of that is also key to understand the biology.
1:21
And now with the breakthrough of immunotherapy, we also know that the immune reaction, the infiltration of the immune cells are also very important.
1:29
So now with a deep analysis of the tumour and an algorithm that is specially trained to identify all this, we can give a much higher precision, much faster and better than the gene analysis.
1:46
The technology can be used in all cancers, but we have focused where the medical need is very high.
1:51
In colorectal cancer, stage 2 and stage 3, 1 million patients every year undergo surgery to remove the cancer and most patients are cured by the surgery.
2:02
However, some patients recur and there will therefore be a very important position for the patient whether to add chemotherapy to reduce the risk of recurrence or to go to observation and remain healthy.
2:16
Because chemotherapy is very toxic, up to half of the patients have serious side effects during treatment, even patients dying from the treatment itself.
2:25
And also after treatment, 1/3 of the patients have serious chronic health issues and never fully recover.
2:31
Also for healthcare systems, this is an important decision because today there's a significant overtreatment leading to unnecessary costs and by implementing our test on a global basis, we can save €3 billion every year.
2:48
So what we have is a digital biomarker.
2:50
You see the test report on the screens, segmenting the tumour and making a risk assessment of the tumour and a total risk scoring of the patient.
3:01
We have the two Lancet publications.
3:03
We have two patent families filed and five grants.
3:07
We have a CE marked products and we're ISO certified, so very mature on that side also.
3:14
So a bit to the data.
3:16
So this is from the one of The Lancet publications where we validated in 1100 patients who received one chemotherapy monotherapy.
3:25
And now today the standard is 2.
3:27
And the second one is very toxic.
3:29
And we categorise the patients in low, intermediate and high risk and you can see very different outcomes for these patients.
3:37
Low risk patients are doing really well and the benefit of chemotherapy in this group is highly questionable.
3:44
So the 40% of these patients are not likely to benefit from chemotherapy.
3:51
That constitutes 250,000 patients every year and a saving of €3 billion.
3:58
But these patients got 1 chemotherapy.
4:01
Now the doublet is the standard, but we also want to show that it also is safe not to treat patients with chemo at all.
4:08
So this is a small cohort from the US, The Ohio State University where we analysed non-treated patients.
4:15
And as you can see it time to in terms of recurrence, very few recurrences in the low risk group compared to the high risk group where 90% to recurred.
4:26
Also for cancer specific survival you will see the same pattern.
4:31
So very solid data only it's a small patient cohort.
4:35
So we now have now expanded to 500 patients that will be presented later this year.
4:42
And then because this is a very high medical need, there are also other technologies coming into the space with ctDNA and liquid biopsies and the MRD minimal residual disease, but it's very expensive and it's also time delaying.
4:59
So what we've seen is that even within the ctDNA negative patients, we can differentiate between the high risk and the low risk patients and that's the MRD negative and the low risk patients seems to have no benefit of chemotherapy at all.
5:19
We also looked a bit deeper into the data.
5:21
So ctDNA was able to catch 60% of the recurrences at the time of the diagnosis.
5:29
We were able to identify 69% of the recurrences.
5:34
And also interestingly together we identify 86% of the recurrences.
5:39
So very complementary technologies.
5:44
Our technology is very scalable.
5:45
We only need the routine slide to be digitised and then we can analyse with our algorithm either in the cloud or integrated in the lab systems and generate a test report.
6:00
And we have a lot of traction also on the commercial side with the commercial vendors, the image management systems and also clinical collaborations so that we can document our products with clinical data.
6:12
That is very important.
6:13
And we have now 2 manuscripts about to be submitted.
6:23
Our main focus of now is the standalone marker in colorectal cancer.
6:28
But there is a potential also to combine with gene analysis, genomic analysis and as I mentioned the liquid biopsies.
6:35
So we have also discussions with multiple partners there to move ahead in a combination setting.
6:44
And we are also moving into other indications, metastatic colorectal cancer, prostate cancer and more.
6:53
So if you're curious to learn more, come by our booth or reach out to us.
7:00
Thank you very much for your attention.